Literature DB >> 8384206

The short loop between epidermal growth factor-like domains 4 and 5 is critical for human thrombomodulin function.

J H Clarke1, D R Light, E Blasko, J F Parkinson, M Nagashima, K McLean, L Vilander, W H Andrews, J Morser, C B Glaser.   

Abstract

Thrombomodulin (TM) is a cofactor for activation of protein C by thrombin. We showed that 80-90% of this cofactor activity is lost by oxidation of Met388, located within the short interdomain loop between epidermal growth factor-like domains 4 and 5 (Glaser, C. B., Morser, J., Clarke, J. H., Blasko, E., McLean, K., Kuhn, I., Chang, R.-J., Lin, J.-H., Vilander, L., Andrews, W. H., and Light, D. R. (1992) J. Clin. Invest. 90, 2565-2573). For each of the 3 amino acids of the loop, site-specific mutants are described in which, 1) all possible single amino acid substitutions are made, 2) deletions are made, or 3) alanine is inserted adjacent to each residue of the loop. Most substitutions within the loop (38/57) result in a > 50% decrease in cofactor activity, while changes in the length of this region result in > 90% loss of activity. Only the Met388-->Leu mutant has higher cofactor activity (2-fold) than wild-type TM. A number of soluble and full-length TM analogs with the Met388-->Leu substitution are improved thrombin cofactors, whether produced in bacteria, insect, or mammalian cells. Detailed kinetic analysis of a soluble TM analog consisting of the six EGF-like domains secreted from insect cells shows that the enhanced activity of the Met388-->Leu mutant results from an increased catalytic efficiency (kcat/Km). This enhancement is maximal at physiological concentrations of calcium. The loss of activity following Met388 oxidation in the wild-type protein is the result of both decreased binding to thrombin (Kd effect) and a decreased interaction of the TM.thrombin complex with protein C (Km effect). We demonstrate the critical role of this interdomain loop in the biological anticoagulant properties of TM.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384206

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Regulation of thrombosis and vascular function by protein methionine oxidation.

Authors:  Sean X Gu; Jeff W Stevens; Steven R Lentz
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

2.  Mutations in the fourth EGF-like domain affect thrombomodulin-induced changes in the active site of thrombin.

Authors:  Julia R Koeppe; Muneera A Beach; Abel Baerga-Ortiz; S Jordan Kerns; Elizabeth A Komives
Journal:  Biochemistry       Date:  2008-09-20       Impact factor: 3.162

3.  A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.

Authors:  H Weiler-Guettler; P D Christie; D L Beeler; A M Healy; W W Hancock; H Rayburn; J M Edelberg; R D Rosenberg
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

4.  Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity.

Authors:  Y Zhang; H Weiler-Guettler; J Chen; O Wilhelm; Y Deng; F Qiu; K Nakagawa; M Klevesath; S Wilhelm; H Böhrer; M Nakagawa; H Graeff; E Martin; D M Stern; R D Rosenberg; R Ziegler; P P Nawroth
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

5.  Highly conserved residue arginine-15 is required for the Ca2+-dependent properties of the gamma-carboxyglutamic acid domain of human anticoagulation protein C and activated protein C.

Authors:  A Thariath; F J Castellino
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

6.  Hypercoagulability Impairs Plaque Stability in Diabetes-Induced Atherosclerosis.

Authors:  Saira Ambreen; Sameen Fatima; Ahmed Elwakiel; Rajiv Rana; Kunal Singh; Anubhuti Gupta; Dheerendra Gupta; Hamzah Khawaja; Jayakumar Manoharan; Christian Besler; Ulrich Laufs; Shrey Kohli; Berend Isermann; Khurrum Shahzad
Journal:  Nutrients       Date:  2022-05-10       Impact factor: 6.706

7.  Thrombin inhibition by cyclic peptides from thrombomodulin.

Authors:  J C Lougheed; C L Bowman; D P Meininger; E A Komives
Journal:  Protein Sci       Date:  1995-04       Impact factor: 6.725

8.  Inactivation of thrombomodulin by ionizing radiation in a cell-free system: possible implications for radiation responses in vascular endothelium.

Authors:  Christopher C Ross; Stewart L MacLeod; Jason R Plaxco; Jeffrey W Froude; Louis M Fink; Junru Wang; Wesley E Stites; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2008-04       Impact factor: 2.841

9.  Molecular basis of thrombomodulin activation of slow thrombin.

Authors:  T E Adams; W Li; J A Huntington
Journal:  J Thromb Haemost       Date:  2009-07-28       Impact factor: 5.824

10.  Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition.

Authors:  S A Maroney; B C Cooley; R Sood; H Weiler; A E Mast
Journal:  J Thromb Haemost       Date:  2007-10-25       Impact factor: 5.824

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.